WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSE:WX
CUSIPN/A
WebN/A
Phone+86-21-50461111
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins7.52%
Return on Equity6.93%
Return on Assets4.67%
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$3,270.00
WuXi PharmaTech (Cayman) (NYSE:WX) Frequently Asked Questions
What is WuXi PharmaTech (Cayman)'s stock symbol?
WuXi PharmaTech (Cayman) trades on the New York Stock Exchange (NYSE) under the ticker symbol "WX."
How were WuXi PharmaTech (Cayman)'s earnings last quarter?
WuXi PharmaTech (Cayman) Inc. (NYSE:WX) posted its earnings results on Tuesday, November, 3rd. The medical research company reported $0.31 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $0.31. The medical research company had revenue of $213.60 million for the quarter, compared to analysts' expectations of $205.24 million. WuXi PharmaTech (Cayman) had a net margin of 7.52% and a return on equity of 6.93%. The business's revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.54 EPS. View WuXi PharmaTech (Cayman)'s Earnings History.
What is the consensus analysts' recommendation for WuXi PharmaTech (Cayman)?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for WuXi PharmaTech (Cayman) in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Has WuXi PharmaTech (Cayman) been receiving favorable news coverage?
Media coverage about WX stock has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. WuXi PharmaTech (Cayman) earned a daily sentiment score of 0.06 on Accern's scale. They also assigned headlines about the medical research company an impact score of 46.78 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of WuXi PharmaTech (Cayman)?
Shares of WX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is WuXi PharmaTech (Cayman)'s stock price today?
One share of WX stock can currently be purchased for approximately $45.91.
How big of a company is WuXi PharmaTech (Cayman)?
WuXi PharmaTech (Cayman) has a market capitalization of $3.27 billion.
How can I contact WuXi PharmaTech (Cayman)?
WuXi PharmaTech (Cayman)'s mailing address is 288 Fute Zhong Road China (Shanghai) Pilot Free Trade Zone, SHANGHAI, SHA 200131, China. The medical research company can be reached via phone at +86-21-50461111.
MarketBeat Community Rating for WuXi PharmaTech (Cayman) (NYSE WX)
MarketBeat's community ratings are surveys of what our community members think about WuXi PharmaTech (Cayman) and other stocks. Vote "Outperform" if you believe WX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WX will underperform the S&P 500 over the long term. You may vote once every thirty days.
